Table 3. irTDs in patients receiving ICIs therapy.
| ICI agent | All (n=42) | Hypothyroidism (n=21) | Hyperthyroidism (n=7) | DH (n=14) | |||
|---|---|---|---|---|---|---|---|
| All | Overt | All | Overt | ||||
| Pembrolizumab | 18 | 8 | 6 | 5 | 3 | 5 | |
| Sintilimab | 12 | 7 | 4 | 1 | 1 | 4 | |
| Atezolizumab | 7 | 3 | 2 | 1 | 1 | 3 | |
| Camrelizumab | 5 | 3 | 1 | 0 | 0 | 2 | |
irTD, immune-related thyroid dysfunction; ICI, immune checkpoint inhibitor; DH, destructive thyroiditis.